(Q39372719)

11 September 2017

0 references

Meta-analysis: The treatment of irritable bowel syndrome (English)

1 reference

11 September 2017

0 references

Lesbros-Pantoflickova D

1

1 reference

11 September 2017

Michetti P

2

1 reference

11 September 2017

Fried M

3

1 reference

11 September 2017

Beglinger C

4

1 reference

11 September 2017

Blum AL

5

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Alimentary Pharmacology & Therapeutics

11 September 2017

published in

1 reference

11 September 2017

volume

20

1 reference

11 September 2017

issue

11-12

1 reference

11 September 2017

page(s)

1253-1269

1 reference

Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Evidence of a genetic contribution to functional bowel disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Irritable bowel syndrome in general practice: prevalence, characteristics, and referral

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

The irritable bowel syndrome: review and a graduated multicomponent treatment approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Antidepressants for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Psychological and sex features of delayed gut transit in functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Irritable bowel syndrome: Assessment of psychological disturbance and its influence on the response to fibre supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Psyllium therapy in the irritable bowel syndrome. A double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Abnormal colonic fermentation in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Colonic tone and motility in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Systematic review: serotonergic modulators in the treatment of irritable bowel syndrome--influence on psychiatric and gastrointestinal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Therapeutic usefulness of amitriptyline in spastic colon syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Irritable colon and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

A systematic review of tegaserod for the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Prucalopride, a systemic enterokinetic, for the treatment of constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

SB-207266: 5-HT4 receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Neurotrophins and hyperalgesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Autonomic regulation of cardiac function during sleep in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Diarrhea- and constipation-predominant IBS patients differ in postprandial autonomic and cortisol responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

Visceral sensation and emotion: a study using hypnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

The treatment of irritable bowel syndrome with hypnotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

The effect of group psychosocial support on survival in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02267.X

10.1111/J.1365-2036.2004.02267.X

21 January 2018

Identifiers

DOI

1 reference

release_g5pmguauarf6hcsmrighip2sdq

11 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/g5pmguauarf6hcsmrighip2sdq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference